The estimated Net Worth of Timothy M Shannon is at least $87.9 million dollars as of 3 September 2021. Timothy Shannon owns over 68,798 units of Arvinas Inc stock worth over $41,146,356 and over the last 15 years he sold ARVN stock worth over $46,468,893. In addition, he makes $250,236 as Independent Chairman of the Board at Arvinas Inc.
Timothy has made over 37 trades of the Arvinas Inc stock since 2010, according to the Form 4 filled with the SEC. Most recently he sold 68,798 units of ARVN stock worth $6,013,633 on 3 September 2021.
The largest trade he's ever made was buying 400,000 units of Arvinas Inc stock on 28 May 2019 worth over $4,000,000. On average, Timothy trades about 36,059 units every 73 days since 2009. As of 3 September 2021 he still owns at least 1,653,128 units of Arvinas Inc stock.
You can see the complete history of Timothy Shannon stock trades at the bottom of the page.
Dr. Timothy Shannon M.D. is Independent Chairman of the Board of the company. Dr. Shannon has been a Non-Managing Member of Canaan Partners IX LLC, a Managing Member of Canaan Partners X LLC, and a Managing Member of Canaan Partners XI LLC, entities affiliated with Canaan Partners, a venture capital firm, since November 2009. From November 2010 to September 2013, Dr. Shannon was the President and Chief Executive Officer of Aldea Pharmaceuticals, a biotechnology company. Dr. Shannon was also Chief Executive Officer of Curagen Corporation from 2007 to 2009 and Chief Medical Officer at Curagen from 2002 to 2007. From 1992 to 2002, Dr. Shannon served in various senior research and development roles at Bayer Healthcare, including Senior Vice President of Worldwide Clinical Development. Dr. Shannon currently serves on the boards of directors of the publicly-traded company Ideaya Biosciences, Inc. and he previously served as a member of the boards of directors of the publicly-traded companies Curagen Corporation, Celldex Therapeutics, Inc., CytomX Therapeutics, Inc. and Nextcure, Inc. Dr. Shannon holds an M.D. from the University of Connecticut and a B.A. in chemistry from Amherst College. Dr. Shannon also served as our interim Chief Executive Officer from July 2013 to December 2014 during which period he was not entitled to severance pay, long-term health and pension benefits or other such standard provisions typically contained in contracts of permanent, non-temporary executives. Shannon is qualified to serve on our board due to his extensive experience in the venture capital industry, his executive leadership experience, his medical background and training, and his service on the boards of other public and private biopharmaceutical companies.
As the Independent Chairman of the Board of Arvinas Inc, the total compensation of Timothy Shannon at Arvinas Inc is $250,236. There are 10 executives at Arvinas Inc getting paid more, with John Houston having the highest compensation of $5,485,840.
Timothy Shannon is 61, he's been the Independent Chairman of the Board of Arvinas Inc since 2014. There are 2 older and 14 younger executives at Arvinas Inc. The oldest executive at Arvinas Inc is Laurie Smaldone Alsup, 66, who is the Independent Director.
Timothy's mailing address filed with the SEC is C/O CANAAN PARTNERS, 2765 SAND HILL ROAD, MENLO PARK, CA, 94025.
Over the last 6 years, insiders at Arvinas Inc have traded over $123,187,141 worth of Arvinas Inc stock and bought 3,567,290 units worth $69,124,444 . The most active insiders traders include Capital Management, L.P.Ra ..., Liam Ratcliffe et Kush Parmar. On average, Arvinas Inc executives and independent directors trade stock every 22 days with the average trade being worth of $1,884,820. The most recent stock trade was executed by John G Houston on 23 February 2024, trading 5,196 units of ARVN stock currently worth $244,472.
arvinas is a pharmaceutical company focused on developing new small molecules ‒ known as protacs (proteolysis targeting chimeras) ‒ aimed at degrading disease-causing cellular proteins via proteolysis. based on innovative research conducted at yale university by dr. craig crews, founder and chief scientific advisor, the company is translating natural protein degradation approaches into novel drugs for the treatment of cancer and other diseases. the proprietary protac-based drug paradigm induces protein degradation, rather than protein inhibition, using the ubiquitin proteasome system and offers the advantage of potentially targeting “undruggable” as well as “druggable” elements of the proteome. this greatly expands the ability to create drugs for many new, previously unapproachable targets. for more information, visit www.arvinas.com.
Arvinas Inc executives and other stock owners filed with the SEC include: